Dashboard
1
With a growth in Net Profit of 132.1%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 2 consecutive quarters
- ROCE(HY) Highest at 7.01%
- RAW MATERIAL COST(Y) Fallen by -5.73% (YoY)
- NET SALES(Q) Highest at CNY 973.24 MM
2
With ROE of 8.73%, it has a attractive valuation with a 1.33 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,145 Million (Mid Cap)
15.00
NA
4.99%
-0.25
8.73%
1.33
Revenue and Profits:
Net Sales:
973 Million
(Quarterly Results - Mar 2026)
Net Profit:
201 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.99%
0%
-6.99%
6 Months
-9.27%
0%
-9.27%
1 Year
-9.58%
0%
-9.58%
2 Years
28.89%
0%
28.89%
3 Years
-38.11%
0%
-38.11%
4 Years
-11.26%
0%
-11.26%
5 Years
-5.25%
0%
-5.25%
Jiuzhitang Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.94%
EBIT Growth (5y)
-5.02%
EBIT to Interest (avg)
89.35
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.61
Tax Ratio
16.30%
Dividend Payout Ratio
114.07%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.18%
ROE (avg)
7.04%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.33
EV to EBIT
12.59
EV to EBITDA
9.80
EV to Capital Employed
1.44
EV to Sales
1.76
PEG Ratio
0.21
Dividend Yield
4.99%
ROCE (Latest)
11.42%
ROE (Latest)
8.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
973.20
601.80
61.71%
Operating Profit (PBDIT) excl Other Income
228.60
113.90
100.70%
Interest
0.40
0.30
33.33%
Exceptional Items
0.50
0.40
25.00%
Consolidate Net Profit
200.60
93.60
114.32%
Operating Profit Margin (Excl OI)
234.80%
136.60%
9.82%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 61.71% vs 65.83% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 114.32% vs 648.80% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,206.80
2,351.00
-6.13%
Operating Profit (PBDIT) excl Other Income
373.60
294.50
26.86%
Interest
1.60
2.80
-42.86%
Exceptional Items
0.40
0.00
Consolidate Net Profit
259.60
215.20
20.63%
Operating Profit Margin (Excl OI)
112.00%
73.20%
3.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -6.13% vs -19.95% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 20.63% vs -27.25% in Dec 2024
About Jiuzhitang Co., Ltd. 
Jiuzhitang Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






